Alyssa Toorop, MD, PhD, Amsterdam University Medical Centers, Amsterdam, The Netherlands, discusses the NEXT-MS trial (NCT04225312) focused on personalized extended interval dosing of natalizumab in relapsing-remitting multiple sclerosis (MS). Although 94% of patients on standard four-week intervals retain high drug concentrations, research suggests extended interval dosing could maintain therapeutic effects, reduce potential side effects, and curtail healthcare costs. The NEXT-MS study aimed to validate personalized dosing efficacy by monitoring drug concentrations. Conducted across 21 Dutch hospitals, the study had participants in three groups, with a focus on target drug concentrations of 10 or 5 micrograms per milliliter. Results revealed that personalized dosing was preferred by 84% of participants and showed no increased disease activity. Moreover, a lower drug concentration target of 5 micrograms per milliliter was found efficacious. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
The NEXT-MS trial was funded by the Dutch MS Research Foundation, the Brain Foundation Netherlands, and Innovation Funds Healthcare insurers. The funding sources had no involvement in the execution of the study.